Medarex and PharmAthene's Valortim Secures Orphan Status
Posted on: Tuesday, 7 March 2006, 12:01 CST
Medarex and PharmAthene's investigational antibody Valortim has been granted FDA orphan drug designation for the treatment of anthrax infection.
Valortim (MDX-1303) is an investigational fully human antibody created using Medarex' UltiMAb human antibody development system that targets the Bacillus anthracis protective antigen.
The investigational antibody is designed to target a protein component known as the anthrax protective antigen of the lethal toxin complex produced by the bacterium. The anthrax protective antigen is believed to initiate the onset of the illness by attaching to cells in the infected person, and then is believed to facilitate the entry of additional destructive toxins into the cells. Valortim is designed to target anthrax protective antigen and protect the cells from damage by the anthrax toxins.
US orphan drug designation will provide important benefits to Valortim's developers, including eligibility for a special seven-year period of market exclusivity upon approval, potential R&D grant funding, and assistance with clinical trial protocol review.
"Despite aggressive antibiotic therapy and supportive care, the anthrax attacks of 2001 resulted in a mortality rate of nearly 50%, illustrating the urgent need for more effective anthrax therapeutics," remarked David Wright, president and CEO of PharmAthene. "Our receipt of orphan drug designation for Valortim and, earlier this year, fast track designation, should facilitate a more streamlined development process through more frequent dialogue with the FDA."
Preclinical studies suggest that Valortim has the potential to provide significant protection against anthrax infection when administered prophylactically, and also may increase survival when administered therapeutically.
Valortim is currently being evaluated in a phase I dose-escalation clinical trial to evaluate the safety, tolerability, immunogenicity, and pharmacokinetics of a single dose of Valortim administered intravenously or intramuscularly in healthy volunteers. Results from this trial are anticipated later this year.
Source: Datamonitor
Related Articles
- National Investigational Trial for Emergency Stroke Care At CDH: One Illinois Hospital Tests New Device That May Reverse Brain Damage Up to 24 Hours After Stroke
- AT-RISK Protection and Investigation to Offer Anti-Piracy Training & Support
- Mirant Adopts Rights Plan Designed to Protect NOLs
- tw telecom Adopts Rights Plan Designed to Protect NOLs
- Genitope Corporation Presents New Data On Its Therapeutic Monoclonal Antibodies To Potentially Treat B-Cell Malignancies
- FDA Grants Orphan Drug Designation to TREANDA, an Investigational Treatment for Chronic Lymphocytic Leukemia
- TechnoVax Reports on a VLP Vaccine Designed to Protect Against the Devastating 1918 Pandemic Influenza As Well As a Novel Bivalent VLP Vaccine Candidate
- Allos Therapeutics Receives FDA Fast Track Designation for PDX for the Treatment of T-Cell Lymphoma
- New Studies Conclude BioThrax(R) Plus Antibiotics Provide 100% Protection in Animals When Administered After Anthrax Exposure
- Dendreon Completes Enrollment in Phase 3 PROTECT (P-11) Clinical Trial of Provenge in Early Stage Prostate Cancer
 |
 |
User Comments (0)
RSS Feeds